Rare Mendelian disorders increasingly contribute to our understanding of the genetic architecture of autoimmune disease and the key molecular pathways governing its pathogenesis. Early-onset autoimmune disease can arise through activating mutations in inflammatory signalling pathways or loss-of-function mutations in immunoregulatory proteins.

We investigated the molecular basis of complex autoimmunity---characterised by the onset of insulin-dependent diabetes, cytopaenias, hepatitis, enteropathy and interstitial lung disease at age 10---in a 14-year-old boy of healthy non-consanguineous British parents. Immunological analysis revealed lymphopaenia with no naive T cells and a high proportion of activated T cells ([table 1](#T1){ref-type="table"}). Pathogenic variants in *STAT3* and *FOXP3* were excluded. The clinical course was refractory to intensive immunosuppression with prednisolone, sirolimus, tacrolimus, infliximab or rituximab, necessitating haematopoietic stem cell transplantation. Twenty-one months post-transplant, he is thriving off all immunosuppressive medication with complete remission of autoimmune disease (except diabetes).

###### 

Immunological and clinical parameters

  -----------------------------------------------------------------------------------------
  Parameters                            Pretransplant   Post-transplant   Reference range
  ------------------------------------- --------------- ----------------- -----------------
  Laboratory                                                              

   Haemoglobin (g/dL)                   9.8             12.4              13.5--17.5

   Leucocytes (10^9^/L)                 1.88            3.47              150--450

   Lymphocytes (10^9^/L)                0.17            1.31              1.2--5.2

   Neutrophils (10^9^/L)                1.52\*          1.79              1.8--8.0

   Monocytes (10^9^/L)                  0.19            0.37              0.2--0.8

   Platelets (10^9^/L)                  29              183               150--400

   CD3+ (cells/µL)                      800             1914              800--3500

   CD8+ (cells/µL)                      554             936               200--1200

   CD4+ (cells/µL)                      238             920               400--1200

   CD56+ (cells/µL)                     35              99                70--1200

   CD19+ (cells/µL)                     138             99                200--600 

   Activated T cells\                   55              25                N/A
   (HLA-DR+ %)                                                            

   CD4+ naive (%)                       Not detected    244               N/A

   CD27-- IgD+ (naive) (%)              87              93                75.2--86.7

   CD27+ IgD+ (memory) (%)              9               4                 4.6--10.2

   CD27+ IgD--\                         2               3                 3.3--9.6
   (class-switched) (%)                                                   

   IgM (g/L)                            0.55            0.25              0.50--1.90

   IgG (g/L)                            6.4             8.2               5.4--16.1

   IgA (g/L)                            0.92            0.33              0.80--2.80

   Tetanus (IU/mL)                      0.93            ND                0.1--10

   *Haemophilus influenzae* b (mg/mL)   1.8             ND                1.0--20.0

   Pneumococcal (mg/mL)                 10              ND                20--200

   Anti-GAD antibody (IU/mL)            \>2000          \>2000            0--9.9

   Islet cell antibody                  Detected        Detected          N/A

   pANCA                                Detected        Detected          N/A

  Clinical                                                                

   FEV~1~ (% predicted)                 38              84                95--100
  -----------------------------------------------------------------------------------------

\*Peripheral neutrophils were supported pretransplant by recombinant granulocyte colony stimulating factor. Post-transplant parameters were obtained at 18 months (FBC and T-cell indices, lung function) or 21 months post-HSCT (B cell and antibody indices). Post-HSCT antibody indices were measured during concomitant subcutaneous immunoglobulin supplementation. No other autoantibodies were detected pre-HSCT or post-HSCT.

FBC, full blood count; FEV~1~, forced expiratory volume in 1 s; GAD, glutamic acid decarboxylase; HLA-DR, human leucocyte antigen--antigen D related; HSCT, haematopoietic stem cell transplantation; ND, not done; pANCA, perinuclear anti neutrophil cytoplasmic antibody.

Ethical approval was granted (ref: 10/H0906/22) and written informed consent provided prior to study commencement. By whole exome sequencing of peripheral blood genomic DNA (Illumina MiSeq) and downstream bioinformatic filtering (Ingenuity Variant Analysis), we identified a single biologically plausible variant---a novel de novo heterozygous 2 bp deletion in tumour necrosis factor-alpha-induced protein 3 (*TNFAIP3*, [figure 1A](#F1){ref-type="fig"}). *TNFAIP3* encodes the ubiquitin-editing enzyme A20, a negative regulator of the nuclear factor-κB (NF-κB) pathway.[@R1] A20 removes K63-linked ubiquitin chains from key adaptor proteins, replacing them with K48-linked polyubiquitin chains, to trigger proteasomal degradation and termination of the NF-κB activation cascade.[@R2] Polymorphisms in *TNFAIP3* have been linked to the development of several autoimmune diseases in genome-wide association studies.[@R3] A conditional knockout of A20 in immune cells leads to the development of autoimmunity in the mouse.[@R8] However, autoimmune phenomena were not prominent in a recently described cohort of patients with germline A20 haploinsufficiency, who instead presented with an autoinflammatory phenotype resembling Behçet's disease.[@R9]

![*TNFAIP3* variant identification and functional validation. (**A**) The family pedigree is shown (triangles are used to preserve the anonymity of healthy unaffected siblings). The first-born infant died as a result of prematurity. Whole exome sequencing data were filtered (Ingenuity Variant Analysis) by confidence (call quality ≥20; read depth ≥10; allele fraction ≥45%); frequency (ExAc allele frequency ≤0.01%); deleteriousness (nonsense/deleterious missense (SIFT/PolyPhen), splice-site disruption); genetic segregation (ie, present in patient and absent from 47 unrelated disease controls) and biological function (linked to phenotype), identifying a single heterozygous frameshift variant in *TNFAIP3* (c.1466_1467TGdel). (**B**) Variant confirmation by Sanger sequencing. (**C**) The c.1466_1467TGdel variant resulted in a frameshift and premature stop codon (V489Afs\*7) in the second ZnF domain and is distinct from previously described mutations in the OTU and ZnF4 domains (blue). (**D**) V489Afs\*7 reduced basal and TNF-induced A20 protein in patient (P) versus control (C1, C2) fibroblasts (immunoblot representative of n=4 independent experiments with n=4 controls). (**E**) Signalling responses downstream of TNF-α stimulation in patient fibroblasts were exaggerated and prolonged compared with control (immunoblot representative of n=4 independent experiments with n=4 controls). (**F**) RNA-seq analysis of transcriptional response to 6-hour TNF-α stimulation in patient and control fibroblasts (stimulations performed in triplicate in a single experiment). Top panel: displayed in red are significant (FDR-corrected p≤0.01) DE transcripts regulated ≥4 fold (≥2log~2~-fold); middle panel: Venn diagram displaying all overlapping DE transcripts ≥2 fold (≥log~2~-fold); Bottom panel: top 20 significant DE transcripts in patient (red bars) versus control (black bars), demonstrating many major NF-κB target genes. (**G**) Levels of IL-6 quantified by ELISA in supernatants from patient and control fibroblasts stimulated with TNF-α for 24 hours (mean±SD of average values from two independent experiments in patient and n=4 controls compared by one-sample t-test; \*\*p=0.0015). DE, differentially expressed; FDR, false discovery rate; IL-6, interleukin 6; NF-κB, nuclear factor-κB; OTU, ovarian tumour; PolyPhen, polymorphism phenotyping; SIFT, Sorting Intolerant from Tolerant; TNF-α, tumour necrosis factor-alpha; TNFAIP3, tumour necrosis factor-alpha-induced protein 3; ZnF, zinc finger.](annrheumdis-2016-210944f01){#F1}

The c.1466_1467delTG variant---which we confirmed by capillary sequencing[@R10] ([figure 1B](#F1){ref-type="fig"})---introduces a frameshift substitution of alanine for valine at position 489, generating a downstream premature stop codon (p.V489Afs\*7) in the zinc finger (ZnF)2 domain of A20. This variant is absent from public databases (ExAc/dbSNP) and distinct from disease-associated mutations affecting the ovarian tumour or ZnF4 domains of A20[@R9] ([figure 1C](#F1){ref-type="fig"}). Immunoblotting[@R10] of patient and control dermal fibroblast lysates with an N-terminal antibody confirmed the reduced basal and TNF-α-induced expression of A20 ([figure 1D](#F1){ref-type="fig"}).

To address the consequence of this reduced A20 expression, we performed functional experiments in patient and control dermal fibroblasts. Initially, we stimulated these cells with TNF-α (10 ng/mL) and analysed downstream signalling events by immunoblot ([figure 1E](#F1){ref-type="fig"}). We observed exaggerated and prolonged phosphorylation of components of the NF-κB pathway, which would be expected to enhance NF-κB-dependent transcriptional effects. In keeping with this prediction, RNA sequencing (Illumina NextSeq-500) revealed a significant global increase in both the range and magnitude of TNF-α-stimulated differential gene expression (fold-change ≥2; false discovery rate-adjusted p≤0.01, [figure 1F](#F1){ref-type="fig"}). We also confirmed enhanced expression of the key NF-κB target gene interleukin 6 (IL-6) at the protein level by ELISA (p=0.0015, [figure 1G](#F1){ref-type="fig"}). In these respects, the molecular consequences of the p.V489Afs\*7 variant were indistinguishable from reported pathogenic A20 mutations,[@R9] although owing to the lack of leucocyte material, we were not able to extend our analysis to inflammasome activation.

Here we provide novel validation of considerable existing evidence that implicates *TNFAIP3* in autoimmune pathogenesis. This case expands the clinical spectrum of A20 haploinsufficiency.[@R9] As A20 regulates multiple innate and adaptive signalling pathways,[@R1] it is logical that patients with inactivating mutations in A20 might manifest pathological features of autoimmunity and/or autoinflammation. Finally, we report that correction of the molecular defect within the haematopoietic cell compartment could represent a viable treatment option for severe clinical manifestations.
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